KT
Therapeutic Areas
NeuroDerm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ND0612 | Parkinson's disease motor fluctuations | Phase 3 |
Leadership Team at NeuroDerm
KI
Kengo Isshiki MSc
CEO
UD
Uri David MSc, MBA
CTO
TY
Tami Yardeni MA
EVP Clinical Development
KB
Karin Baer BSc
VP Quality
LS
Lilach Shmueli-Dayan MBA
VP Finance
OE
Ofer Ekbali MBA
VP Operations & Interim VP Pharmaceutical Development
ZM
Ziva Mesika BSc
VP Regulatory Affairs
TT
Toshifumi Tada MBA
Board Chair